Related Experiment Video

Updated: Dec 7, 2025

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

24.8K

Therapeutic Potential of Senolytics in Cardiovascular Disease

Emily Dookun1, João F Passos2, Helen M Arthur1

  • 1Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE1 3BZ, UK.

Cardiovascular Drugs and Therapy
|September 26, 2020
PubMed

Insights

Ageing significantly increases cardiovascular disease risk. Eliminating senescent cells with senolytics may treat cardiovascular ageing and related diseases.

Area of Science:

  • Cardiovascular Science
  • Gerontology
  • Cellular Biology

Background:

  • Ageing is the primary risk factor for cardiovascular disease (CVD), leading to significant mortality in older adults.
  • Age-associated CVD includes heart failure, coronary artery disease, and myocardial infarction, with poorer prognoses in the elderly.
  • Accumulation of senescent cells contributes to cardiovascular ageing and disease progression via a senescence-associated secretory phenotype.

Purpose of the Study:

  • To review the role of senescent cells in cardiovascular ageing.
  • To explore senolytics as a therapeutic strategy for age-associated cardiovascular diseases.

Main Methods:

  • Review of genetic models demonstrating the impact of senescent cell elimination.
  • Analysis of studies investigating the senescence-associated secretory phenotype.
  • Examination of senolytic compounds targeting senescent cell apoptosis.

Main Results:

  • Senescent cell accumulation drives cardiovascular ageing pathophysiology.
  • The senescence-associated secretory phenotype promotes inflammation and fibrosis in the cardiovascular system.
  • Senolytics show potential for ameliorating age-associated cardiovascular conditions.

Conclusions:

  • Targeting senescent cells represents a promising therapeutic avenue for cardiovascular ageing.
  • Senolytics offer a novel approach to combatting age-related cardiovascular decline and disease.

Keywords:
AtherosclerosisCardiovascularInflammationRemodellingSenescenceSenolytic

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
726
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
123
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
223
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.0K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
612
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.6K